axicabtagene ciloleucel
gilead sciences,daiichi sankyo
['axicabtagene ciloleucel', 'lymphoma']
are pretreatment tumor characteristics associated with outcomes following second-line treatment with axicabtagene ciloleucel vs. soc in patients with relapsed/refractory large b-cell #lymphoma? check out poster #218 tomorrow at #asco. 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. For news and stories visit https://t.co/XaP6iv4q19.